RPS5 and cancer: Thus, as protein landscapes are increasingly used to understand tumorigenesis and find novel cancer therapeutic targets that are not driver gene products (49), our chemoproteoinformatics approach may provide novel opportunities for screening and validating RPS5-binding ligands for use as cancer therapeutics in combination with the MEK inhibitor in the postgenome era.